Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引:20
作者
Takimoto, Takayuki [1 ]
Nakabori, Tasuku [1 ]
Osa, Akio [1 ]
Morita, Satomu [1 ]
Terada, Haruko [1 ]
Oseto, Susumu [1 ]
Iwazawa, Takashi [2 ]
Abe, Kinya [1 ]
机构
[1] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan
[2] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka 5608565, Japan
关键词
Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; beta(2)-Microglobulin; RENAL-FUNCTION; CISPLATIN; CHEMOTHERAPY; PLATINUM; TAXOTERE;
D O I
10.1007/s10147-011-0304-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.
引用
收藏
页码:395 / 398
页数:4
相关论文
共 50 条
[41]   Maintenance therapy in non-small-cell lung cancer [J].
Stinchcombe, Thomas E. ;
West, Howard L. .
LANCET, 2009, 374 (9699) :1398-1400
[42]   First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study [J].
Georgoulias, V ;
Androulakis, N ;
Dimopoulos, AM ;
Kourousis, C ;
Kakolyris, S ;
Papadakis, E ;
Apostolopoulou, F ;
Papadimitriou, C ;
Vossos, A ;
Agelidou, M ;
Heras, P ;
Tzannes, S ;
Vlachonicolis, J ;
Mavromanolakis, E ;
Hatzidaki, D .
ANNALS OF ONCOLOGY, 1998, 9 (03) :331-334
[43]   Elderly patients treatment with non-small-cell lung cancer [J].
Kowalski, Dariusz M. ;
Krzakowski, Maciej .
ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (01) :29-35
[44]   Chemotherapy of elderly patients with non-small-cell lung cancer [J].
Kloke, O .
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2001, 34 (04) :277-279
[45]   Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review [J].
Blinman, Prunella ;
Alam, Mahmood ;
Duric, Vlatka ;
McLachlan, Sue-Anne ;
Stockler, Martin R. .
LUNG CANCER, 2010, 69 (02) :141-147
[46]   Nivolumab-refractory patients with advanced non-small-cell lung cancer [J].
Costantini, A. ;
Fallet, V. ;
Corny, J. ;
Friard, S. ;
Chouaid, C. ;
Duchemann, B. ;
Giroux-Leprieur, E. ;
Taillade, L. ;
Doucet, L. ;
Brosseau, S. ;
Wislez, M. ;
Tredaniel, J. ;
Cadranel, J. .
LUNG CANCER, 2019, 130 :128-134
[47]   Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer [J].
Kim, Young Hak ;
Yoh, Kiyotaka ;
Niho, Seiji ;
Goto, Koichi ;
Ohmatsu, Hironobu ;
Kubota, Kaoru ;
Nishiwaki, Yutaka .
RESPIRATORY MEDICINE, 2010, 104 (03) :434-439
[48]   Efficacy of docetaxel in non-small-cell lung cancer patients previously treated with paltinum-containing chemotherapy [J].
Robinet, G ;
Thomas, P ;
Pérol, M ;
Vergnenègre, A ;
Lena, H ;
Taytard, A ;
Paillotin, D ;
Bessa, EH ;
Schuller-Lebeau, MP .
REVUE DES MALADIES RESPIRATOIRES, 2000, 17 (01) :83-89
[49]   Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer [J].
Tsunoda, T ;
Koizumi, T ;
Hayasaka, M ;
Hirai, K ;
Koyama, S ;
Takabayashi, Y ;
Fujimoto, K ;
Kubo, K .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (02) :173-177
[50]   Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer [J].
Toshiyuki Tsunoda ;
Tomonobu Koizumi ;
Muneharu Hayasaka ;
Kazuya Hirai ;
Shigeru Koyama ;
Yasuki Takabayashi ;
Keisaku Fujimoto ;
Keishi Kubo .
Cancer Chemotherapy and Pharmacology, 2004, 54 :173-177